Luminor Capital

Ayondo is a technology company that specializes in providing a social trading platform along with spread betting and contract for difference (CFD) services. Founded in 2008 and headquartered in London, Ayondo's proprietary technology allows users to automatically copy the trading actions of top traders, enhancing the trading experience for individual investors. The company's TradeHub platform facilitates the trading of a wide range of CFD instruments, including forex currency pairs, major indices, interest rates, and precious metals, all while offering zero tax on capital gains. Ayondo's services are accessible via various mobile devices, including smartphones and tablets running iOS and Android. Although the company was previously more active in brokerage services, it has shifted focus toward its technology-driven trading platforms.

Ayondo is a technology company that specializes in providing a social trading platform along with spread betting and contract for difference (CFD) services. Founded in 2008 and headquartered in London, Ayondo's proprietary technology allows users to automatically copy the trading actions of top traders, enhancing the trading experience for individual investors. The company's TradeHub platform facilitates the trading of a wide range of CFD instruments, including forex currency pairs, major indices, interest rates, and precious metals, all while offering zero tax on capital gains. Ayondo's services are accessible via various mobile devices, including smartphones and tablets running iOS and Android. Although the company was previously more active in brokerage services, it has shifted focus toward its technology-driven trading platforms.

TriReme Medical, Inc. is a privately held medical device company based in Pleasanton, California, founded in 2005. The company focuses on developing and manufacturing innovative stent technologies aimed at treating coronary artery disease, particularly at or near bifurcations. TriReme Medical specializes in advanced therapeutic systems, creating next-generation percutaneous devices for both coronary and peripheral vascular diseases. Its unique balloon and stent therapies address significant unmet clinical needs within these complex medical markets, offering physicians differentiated solutions designed to enhance patient outcomes in challenging vascular interventions.